Skip to main content
. Author manuscript; available in PMC: 2010 Feb 1.
Published in final edited form as: Cancer Res. 2009 Feb 1;69(3):775–784. doi: 10.1158/0008-5472.CAN-08-0987

Figure 4. CCN2 knockdown decreases subcutaneous and orthotopic tumor growth, and increases the survival of orthotopic tumor-bearing mice.

Figure 4

(A) 107 wild-type, CCN2 over-expressing, and CCN2 shRNA-expressing Panc-1 clones were subcutaneously implanted in nu/nu mice. Tumor volumes were monitored weekly using calipers. Panc-1 + CCN2 shRNA (pool) curve is included from Figure 2A for visual comparison purposes only. Data are mean ± SEM with at least 5 mice per group; *p<0.05 by ANOVA of AUCs.

(B) 107 wild-type, CCN2 over-expressing, or CCN2 shRNA-expressing Panc-1 cells were orthotopically implanted in nu/nu mice. Tumor volume was monitored by uptake of intravenously administered 18F-deoxyglucose (FDG) using positron emission tomography (PET). Representative maximum intensity projections are shown, with regions of high FDG uptake highlighted. G = Harderian glands, H = heart, K = kidney, B = bladder, T = tumor.

(C) Survival plot of mice bearing orthotopic pancreatic tumors. Data from 3-9 mice per group; p-values indicate comparison with mice bearing wild-type tumors by log-rank test.